1
|
Borie F, Dubray V, Tretarre B. Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis. Clin Res Hepatol Gastroenterol 2022; 46:101856. [PMID: 34963650 DOI: 10.1016/j.clinre.2021.101856] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 10/17/2021] [Accepted: 12/14/2021] [Indexed: 02/04/2023]
Abstract
OBJECTIVE To assess the prognostic impact of the new therapies recommended over the past twenty years for colonic cancers with synchronous hepatic metastasis (hmCC). METHODS From 1995 to 2016, 802 hmCC were identified in a tumor registry. An univariate and multivariate analysis looked for the impact of the different recommendations over three periods: chemotherapy without targeted therapy (p1CH), chemotherapy with targeted agent in 2nd line (p2TA2), chemotherapy with TA in 1st line (p3TA1) depending on anatomoclinical criteria and therapeutic sequences: chemotherapy then resection of the primary tumor (CR) (n = 100), resection of the primary tumor then chemotherapy (RC) (n = 541), chemotherapy alone with or without TC (onlyCH) (n = 161). RESULTS The rates of onlyCH, CR and RC had varied respectively during these 3 periods from 12% to 26%, 6% to 21% and from 82% to 53% (p = 0.001). The medians of p1CH, p2TA2 and p3TA1 survival were 20.2, 22.7 and 23.6 months, respectively (p = 0.12). The independent factors of poor prognosis were age ≥ 75 years (1.6 [1.35; 1.9] p = 0.0001), chemotherapy only 2.3 [1.6; 3.5] p = 0.0001), p1CH 1.7 [1.4; 2.1] p<0.0001), p2TA2 1.2 [1.02;1.6] p = 0.04. The p2TA2 period had a worse prognosis than p3TA1 (1.25 [1.01; 1.5] p = 0.03). CONCLUSION In public health point of view, the recommendation of first-line TA improved survival and increased rate of primary tumor resection after chemotherapy.
Collapse
Affiliation(s)
- Frederic Borie
- Registre des tumeurs, Parc Euromedecine, 208 rue des Apothicaires 34298 Montpellier, France; Research Unit INSERM University of Montpellier, IDESP Institute Desbrest of Epidemiology and Public Health, Montpellier, France; Department of Digestive surgery, CHU Carémeau, Place du Pr Debré, 30 090 Nîmes, France.
| | - Vincent Dubray
- Registre des tumeurs, Parc Euromedecine, 208 rue des Apothicaires 34298 Montpellier, France
| | - Brigitte Tretarre
- Registre des tumeurs, Parc Euromedecine, 208 rue des Apothicaires 34298 Montpellier, France
| |
Collapse
|
2
|
Have French recommendations had an impact on the treatment and survival of middle and lower rectal cancer patients? Clin Res Hepatol Gastroenterol 2012; 36:156-61. [PMID: 22138062 DOI: 10.1016/j.clinre.2011.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2011] [Revised: 08/22/2011] [Accepted: 10/26/2011] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Compare the survival of middle and lower rectal cancer (MLRC) patients before and after the 1994 issue of rectal cancer (RC) consensus conference recommendations. METHODS Cases of MLRC noted in the Hérault department of France in 1992 (n=58) and 2000 (n=93) yielded exhaustive epidemiological, clinical-pathological and treatment data that were used to compare MLRC patient management and survival in these two periods. RESULTS Significantly more lymph nodes (≥ 8) were harvested in 2000 (≥ 8, 47%) than in 1992. In all, 45 patients (77.6%) received radiotherapy in 1992, and 74 (82%) in 2000. Chemotherapy was employed in 15 patients (25.9%) in 1992 and in 39 patients (43%) in 2000. Chemotherapy and radiotherapy, together with sphincter conservation, were dependent upon the year. Overall 5-year relative survival for rectal cancer in the Hérault department did not vary between 1992 (56%) and 2000 (56%). Independent poor prognostic factors were the same in both years: age over 75 years, lymph node involvement and metastases. Management place and year had no significant impact on prognosis. CONCLUSION The recommendations made have had little impact on disease management and the quality of anatomic pathology reports, and have not improved 5-year relative survival.
Collapse
|
3
|
Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, Heriot AG, Leblanc F, Delaney CP. International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. World J Surg 2010; 34:2689-700. [PMID: 20703471 PMCID: PMC2949570 DOI: 10.1007/s00268-010-0738-3] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Little is known regarding variations in preoperative treatment and practice for rectal cancer (RC) on an international level, yet practice variation may result in differences in recurrence and survival rates. METHODS One hundred seventy-three international colorectal centers were invited to participate in a survey of preoperative management of rectal cancer. RESULTS One hundred twenty-three (71%) responded, with a majority of respondents from North America, Europe, and Asia. Ninety-three percent have more than 5 years' experience with rectal cancer surgery. Fifty-five percent use CT scan, 35% MRI, 29% ERUS, 12% digital rectal examination and 1% PET scan in all RC cases. Seventy-four percent consider threatened circumferential margin (CRM) an indication for neoadjuvant treatment. Ninety-two percent prefer 5-FU-based long-course neoadjuvant chemoradiation therapy (CRT). A significant difference in practice exists between the US and non-US surgeons: poor histological differentiation as an indication for CRT (25% vs. 7.0%, p = 0.008), CRT for stage II and III rectal cancer (92% vs. 43%, p = 0.0001), MRI for all RC patients (20% vs. 42%, p = 0.03), and ERUS for all RC patients (43% vs. 21%, p = 0.01). Multidisciplinary team meetings significantly influence decisions for MRI (RR = 3.62), neoadjuvant treatment (threatened CRM, RR = 5.67, stage II + III RR = 2.98), quality of pathology report (RR = 4.85), and sphincter-saving surgery (RR = 3.81). CONCLUSIONS There was little consensus on staging, neoadjuvant treatment, and preoperative management of rectal cancer. Regular multidisciplinary team meetings influence decisions about neoadjuvant treatment and staging methods.
Collapse
Affiliation(s)
- Knut M. Augestad
- Division of Colorectal Surgery, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106-5047 USA
- Department of Gastrointestinal Surgery, University Hospital of North Norway, Tromsø, Norway
- Department of Telemedicine and Health Service Research, University Hospital of North Norway, Tromsø, Norway
| | - Rolv-Ole Lindsetmo
- Division of Colorectal Surgery, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106-5047 USA
- Department of Gastrointestinal Surgery, University Hospital of North Norway, Tromsø, Norway
- Institute of Clinical Medicine, Tromsø University, Tromsø, Norway
| | - Jonah Stulberg
- Division of Colorectal Surgery, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106-5047 USA
- Department of Biostatistics and Epidemiology, Case Western Reserve University School of Medicine, Cleveland, OH 44106 USA
| | - Harry Reynolds
- Division of Colorectal Surgery, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106-5047 USA
| | - Anthony Senagore
- Spectrum Health Care, Department of Surgery, Michigan State University, Grand Rapids, MI 49503 USA
| | - Brad Champagne
- Division of Colorectal Surgery, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106-5047 USA
| | - Alexander G. Heriot
- Division of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Fabien Leblanc
- Department of Digestive Surgery, University Hospitals of Bordeaux, Bordeaux, France
| | - Conor P. Delaney
- Division of Colorectal Surgery, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106-5047 USA
| | | |
Collapse
|
4
|
Bonaventure T, Goéré D, Boige V, Pocard M. Méfiez vous du TEP-scan en cas de cancer sur maladie inflammatoire chronique de l’intestin. ACTA ACUST UNITED AC 2009; 146:579-82. [DOI: 10.1016/j.jchir.2009.10.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|